Clearmind Medicine Inc. announced its Annual and Special Meeting of Shareholders to be held virtually on January 6, 2025. The company will seek approval for several key matters including fixing the board size at five directors and electing directors for the ensuing year.A significant proposal includes authorizing a share consolidation of up to 50:1 ratio, allowing the board to implement the consolidation within 12 months following the meeting. The consolidation aims to increase share price and potentially attract institutional investors, while maintaining flexibility in determining the final ratio based on market conditions.The meeting will also consider appointing Brightman Almagor Zohar & Co. as auditor and approving a new omnibus equity incentive plan with a 20% ceiling on total issuable shares. The plan includes provisions for stock options, restricted share units, and stock awards, subject to various vesting and holding period requirements.

Clearmind Medicine Inc. announced its Annual and Special Meeting of Shareholders to be held virtually on January 6, 2025. The company will seek approval for several key matters including fixing the board size at five directors and electing directors for the ensuing year.A significant proposal includes authorizing a share consolidation of up to 50:1 ratio, allowing the board to implement the consolidation within 12 months following the meeting. The consolidation aims to increase share price and potentially attract institutional investors, while maintaining flexibility in determining the final ratio based on market conditions.The meeting will also consider appointing Brightman Almagor Zohar & Co. as auditor and approving a new omnibus equity incentive plan with a 20% ceiling on total issuable shares. The plan includes provisions for stock options, restricted share units, and stock awards, subject to various vesting and holding period requirements.